Imagion Biosystems advances MagSense breast cancer trial toward U.S. Phase 2 start

Imagion Biosystems Ltd. ( (AU:IBX) ) has shared an update.

Imagion Biosystems has submitted its first Investigational New Drug application to the U.S. Food and Drug Administration for a Phase 2 clinical trial of its MagSense imaging agent in HER2-positive breast cancer patients. The company has completed engagement with four U.S. clinical sites, progressed contract negotiations, and advanced manufacturing preparations so the study can start quickly once the IND is approved, which is anticipated in the second quarter of 2026.

The planned Phase 2 trial will evaluate safety, dosing, imaging schedule and diagnostic performance across a three-part design, and is expected to conclude 18 to 24 months after IND acceptance. Results are intended not only to validate MagSense in detecting nodal metastases and inform its clinical and economic value, but also to generate quantitative imaging data to support AI diagnostic tools, while an amended convertible note with Mercer Street provides an additional $300,000 and extended maturities to help fund these activities.

More about Imagion Biosystems Ltd.

Imagion Biosystems Ltd. is an Australian medical technology company focused on improving cancer care through early detection using its proprietary MagSense imaging technology. The company is developing targeted imaging agents, with a primary focus on HER2-positive breast cancer, and is advancing its products through clinical trials to support regulatory approval and potential commercialization in oncology diagnostics.

Average Trading Volume: 1,744,631

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$10.3M

For an in-depth examination of IBX stock, go to TipRanks’ Overview page.